Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.
Sheng Yang(Fujian Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Shuxiang Zhang(University of Jinan), Shiyu Jiang(Second Affiliated Hospital of Zhejiang University), Sheng Yao(BioReliance (United States)), Jiarui Yao(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Liu(Jiangxi University of Traditional Chinese Medicine), Ying Han(Fujian University of Traditional Chinese Medicine), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhishang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hui Feng(Boston University)
Cited by 5
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
|Blood|2010|323
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287